1. Home
  2. MAMA vs PGEN Comparison

MAMA vs PGEN Comparison

Compare MAMA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mama's Creations Inc.

MAMA

Mama's Creations Inc.

HOLD

Current Price

$15.62

Market Cap

649.2M

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.10

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAMA
PGEN
Founded
2010
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
649.2M
1.4B
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
MAMA
PGEN
Price
$15.62
$4.10
Analyst Decision
Strong Buy
Buy
Analyst Count
5
5
Target Price
$17.80
$8.33
AVG Volume (30 Days)
281.9K
5.2M
Earning Date
04-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.08
N/A
Revenue
$95,420,129.00
$230,981,000.00
Revenue This Year
$40.92
$1,115.92
Revenue Next Year
$29.52
$81.04
P/E Ratio
$194.88
N/A
Revenue Growth
95.54
N/A
52 Week Low
$6.07
$1.23
52 Week High
$17.85
$5.47

Technical Indicators

Market Signals
Indicator
MAMA
PGEN
Relative Strength Index (RSI) 51.29 57.90
Support Level $15.36 $4.02
Resistance Level $16.87 $4.44
Average True Range (ATR) 0.58 0.32
MACD 0.03 0.12
Stochastic Oscillator 73.84 83.08

Price Performance

Historical Comparison
MAMA
PGEN

About MAMA Mama's Creations Inc.

Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: